Real-life Efficacy of Omalizumab After 9 Years of Follow-up

Francesco Menzella; Carla Galeone; Debora Formisano; Claudia Castagnetti; Patrizia Ruggiero; Anna Simonazzi; Luigi Zucchi

추천

검색

자료유형: 학술저널

저자정보: Francesco Menzella (Department of Cardio-Thoracic-Vascular and Intensive Care Medicine Pneumology Unit Arcispedale Sa) Carla Galeone (Arcispedale Santa Maria Nuova-IRCCS) Debora Formisano (Arcispedale Santa Maria Nuova-IRCCS) Claudia Castagnetti (Arcispedale Santa Maria Nuova-IRCCS) Patrizia Ruggiero (Arcispedale Santa Maria Nuova-IRCCS) Anna Simonazzi (Arcispedale Santa Maria Nuova-IRCCS) Luigi Zucchi (Arcispedale Santa Maria Nuova-IRCCS)

저널정보: 대한천식알레르기학회(구 대한알레르기학회) Allergy, Asthma & Immunology Research Allergy, Asthma & Immunology Research Vol.9 No.4

발행연도: 2017.1

수록면: 368 - 372 (5page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Omalizumab is frequently used as add-on treatment to inhaled corticosteroids (ICS) and long-acting β2-agonists in patients with suboptimal control of severe asthma. Patients with severe asthma will typically require chronic treatment, although due to the limited amount of data available there are still some concerns about the safety and efficacy of long-term therapy with omalizumab. Herein, in an extension of a previous 4-year study, we report disease-related outcomes of 8 patients with severe persistent allergic asthma who have been followed for a total of 9 years in a real-life setting. Both quality of life (QoL) (evaluated using the Juniper Asthma-Related QoL Questionnaire [AQLQ]) and forced expiratory volume in 1 second (FEV1) showed sustained improvement at 9 years. The median values of AQLQ and FEV1 at 4 years were 5.5 and 82.0% compared to 5.9 and 85.5%, respectively, at 9 years, which were all significantly increased from baseline. After 9 years, the mean annual number of severe exacerbations was 0.63 compared to 5 at baseline. There also appeared to be a trend toward use of a lower dose of ICS at longer follow-up times. After 9 years, there were no safety concerns for continued use of omalizumab, and no asthma-related hospitalizations or emergency department visits were documented over the last 5 years. The present analysis is the longest reported clinical follow-up of omalizumab. Long-term maintenance treatment with omalizumab for up to 9 years is associated with continued benefits in reducing symptoms, exacerbations, and medication burden without any safety concerns.

참고문헌 (18)

참고문헌 신청

Barnes PJ / 1996 / The costs of asthma / Eur Respir J 9:636~642

Bateman ED / 2008 / Global strategy for asthma management and prevention:GINA executive summary / Eur Respir J 31:143~178

Bateman ED / 2004 / Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study / Am J Respir Crit Care Med 170:836~844

Cazzoletti L / 2007 / Asthma control in Europe: a real-world evaluation based on an international population-based study / J Allergy Clin Immunol 120:1360~1367

Merritt L. Fajt / 2017 / Development of New Therapies for Severe Asthma / Allergy, Asthma & Immunology Research 9(1):3~14

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

Francesco Menzella

소속기관 Department of Cardio-Thoracic-Vascular and Intensive Care Medicine Pneumology Unit Arcispedale Sa

주요연구분야 의약학 > 임상의학 > 내과학

논문수 1 이용수 0

Carla Galeone